ArticleInvestigative ophthalmology & visual science2026
Ferroptosis: A Novel Mechanism in Diabetic Keratopathy.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate whether ferroptosis, an iron-dependent form of cell death, contributes to diabetic keratopathy (DK) by integrating evidence from human tissues, a diabetic mouse model, and in vitro studies and to explore the potential of ferroptosis inhibitor as a therapeutic strategy. Methods: Human diabetic and nondiabetic corneal biopsy tissues were examined for iron accumulation using Prussian blue staining. In a streptozotocin-induced diabetic mouse model, corneal iron staining and transferrin receptor 1 (TfR1) expression were assessed. Primary human corneal epithelial cells were exposed to high glucose for 3 days to evaluate iron staining, 4-hydroxynonenal and reactive oxygen species production, and protein expression of TfR1 and glutathione peroxidase 4 (GPX4). To probe the mechanism, human corneal epithelial cells were treated with the ferroptosis inhibitor ferrostatin-1 (Fer-1) and assessed for iron, ROS, proliferation, migration, protein expression, and cell viability. Results: Diabetic human and mouse corneas showed significantly increased iron staining. In mice, the staining correlated with elevated TfR1 expression. In vitro, high glucose induced iron accumulation, increased 4-hydroxynonenal and ROS, and altered protein expression (increased TfR1 and decreased GPX4). Fer-1 reduced high glucose-induced iron accumulation and ROS, restored GPX4, and improved proliferation, migration, and viability; TfR1 levels remained unchanged. Conclusions: These findings suggest that ferroptosis plays an important role in DK. High glucose triggers this pathway by increasing iron and disrupting antioxidant defense. Targeting ferroptosis with inhibitors such as Fer-1 may have potential relevance in DK, but further studies are needed to clarify its therapeutic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.